UnitedHealth Group, Inc.

As of October 31, 2025, UnitedHealth Group, Inc. shows a mildly bearish trend, with a year-to-date return of -34.02% compared to the S&P 500's 16.30%, driven by bearish daily moving averages and longer-term indicators despite some bullish signals.

As of October 31, 2025, UnitedHealth Group, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -32.48% compared to the S&P 500's 16.30%.

As of October 31, 2025, UnitedHealth Group's technical trend is mildly bearish, with mixed signals from various indicators, and it has significantly underperformed the S&P 500, showing a year-to-date return of -32.48% compared to the S&P 500's 16.30%.

As of October 10, 2025, UnitedHealth Group, Inc. is in a mildly bearish trend with mixed technical indicators, showing a year-to-date return of -29.92% compared to the S&P 500's 11.41%.

As of October 10, 2025, UnitedHealth Group, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly with a year-to-date return of -29.92% compared to the S&P's 11.41%.

As of October 3, 2025, UnitedHealth Group's technical trend is neutral with mixed signals, showing a yearly underperformance of -39.31% against the S&P 500, but a strong 1-month return of 13.75%.

As of October 3, 2025, UnitedHealth Group's technical trend is neutral with mixed signals, showing mild bullishness on the weekly MACD and RSI, while underperforming the S&P 500 year-to-date with a return of -28.79%.

As of October 3, 2025, UnitedHealth Group's technical trend is neutral with mixed signals, showing mild bullishness in some indicators while underperforming the S&P 500 year-to-date with a return of -28.79%.

As of September 9, 2025, UnitedHealth Group's technical trend is neutral with mixed indicators, showing a year-to-date return of -33.81% compared to the S&P 500's 12.22%.

As of September 9, 2025, UnitedHealth Group, Inc. is considered overvalued with a P/E ratio of 12, an EV to EBITDA ratio of 77.36, and a year-to-date return of -33.81%, significantly underperforming the S&P 500.

As of October 5, 2023, UnitedHealth Group, Inc. is considered attractive and undervalued with a P/E ratio of 20.5, a P/B ratio of 4.0, and a 25% ROE, despite trading at a premium compared to peers like Anthem and Cigna, due to its strong growth prospects and recent outperformance against the Sensex.

As of November 1, 2023, there is insufficient technical data to determine if UnitedHealth Group, Inc. is bullish or bearish.

As of March 2022, the management team of UnitedHealth Group, Inc. includes Non-Executive Chairman Stephen Hemsley, Lead Independent Director Richard Burke, and Independent Directors William Ballard, Timothy Flynn, and Michele Hooper. They are responsible for the company's governance and oversight.

UnitedHealth Group, Inc. is a large health and well-being company in the Healthcare Services industry, with a market cap of approximately $280 billion and a recent net profit of $6.47 billion. Key metrics include a P/E ratio of 12.00 and a dividend yield of 209.00%.

As of Jun 18, UnitedHealth Group, Inc. has a market capitalization of $280.19 billion, with a net profit of $22.94 billion over the last four quarters and total assets of $302.10 billion.